Assays from HYPHEN BioMed for monitoring recombinant activated Factor VII (rFVIIa/NovoSeven®/eptacog alfa) bypassing agent therapy in hemophilia A and B patients with inhibitors.
HEMOCLOT™ Factor VIIa is a clotting-based assay using Factor VII-deficient plasma substrate for selective FVIIa activity measurement. BIOPHEN™ Factor VIIa provides a parallel chromogenic approach for FVIIa quantification in purified medium. Both assays require FVIIa-specific calibrators (BIOPHEN™ Calibrator FVIIa) — standard FVII calibrators cannot be used for FVIIa activity quantification due to different specific activity profiles. BIOPHEN™ FVIIa Control Set (two levels) enables ongoing QC.
Page(s):
<
>
1
| Reference | Product Name | Price | ||
|
|
ACK092K-RUO
|
HEMOCLOT™ Factor VIIa — FVIIa Clotting Assay for Bypassing Therapy | $659.00 | |
|
|
A221312-MIN
|
BIOPHEN™ Factor VIIa — FVIIa Activity Chromogenic Assay | $636.00 | |
|
|
A226301-RUO
|
BIOPHEN™ FVIIa Calibrator — Activated Factor VII Calibration Set | $346.00 | |
|
|
A224901-RUO-MIN
|
BIOPHEN™ FVIIa Control Set — Activated FVII Quality Control | $255.00 |